Protocol for the Treatment of Patients With Previously Untreated Chronic Lymphocytic Leukemia

Chronic Lymphocytic Leukemia Clinical Trial

Official title:

Phase II Clinical Protocol for the Treatment of Patients With Previously Untreated Chronic Lymphocytic Leukemia

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00280241
• Other study ID #: 03-136
• Status: Completed
• Phase: Phase 2
• First received: January 19, 2006
• Last updated: January 5, 2016
• Start date: June 2004
• Est. completion date: January 2013

Study information

• Verified date: January 2016
• Source: University of Pittsburgh
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Food and Drug Administration
• Study type: Interventional

Clinical Trial Summary

This research study will look at the effects (good or bad) of administering cyclophosphamide, fludarabine, and rituximab. Clinical studies with combination therapy have shown higher response rates than using single drugs, and this study will evaluate the side effects and effectiveness of this combination.

Description:

This study is designed to expand on the highly successful combination of rituximab, fludarabine and cyclophosphamide for patients with previously untreated CLL. Responses in the range of 90-98% with 55% complete responses are reported. However, bone marrow toxicity has been a significant problem. This trial is designed to reduce the bone marrow toxicity by decreasing the doses of fludarabine and cyclophosphamide, but doubling the dose of rituximab with a maintenance dose of rituximab for up to two years, to maintain or even enhance efficacy.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 65
• Est. completion date: January 2013
• Est. primary completion date: February 2008
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Diagnosis of CD20 + CLL

• Peripheral blood absolute lymphocyte count of > 5,000/mm3 obtained within 2 weeks prior to randomization.

• The lymphocytosis must consist of small to moderate size lymphocytes, with =55% (no greater than 55%) prolymphocytes, atypical lymphocytes, or lymphoblasts morphologically.

• Phenotypically characterized CD20 + CLL defined as: 1) the predominant population of cells share B-cell antigens with CD5 in the absence of other pan-T-celI markers (CD3, CD2, etc.); 2) B-cell expresses either kappa or lambda light chains; and 3) surface immunoglobulin (slg) with low-cell surface density expression.

• Splenomegaly, hepatomegaly or lymphadenopathy are not required for the diagnosis of CLL.

• Must require chemotherapy. Indications for chemotherapy are one or more of the following:

• One or more of the following disease-related symptoms

• Weight loss >10% within the previous 6 months.

• Fevers of greater than 100.0° F for 2 weeks without evidence of infection.

• Night sweats without evidence of infection.

• Evidence of progressive marrow failure as manifested by the development of or worsening of anemia (< 10 g/dl) and/or thrombocytopenia (< 100,000/mm3).

• Massive (i.e., > 6 cm below left costal margin) or progressive splenomegaly.

• Massive nodes or clusters (i.e., > 10 cm in longest diameter) or progressive

• adenopathy.

• Progressive lymphocytosis with an increase of> 50% over 2 month period, or an anticipated doubling time of less than 6 months.

• NOTE: Marked hypogammaglobulinemia or the development of a monoclonal protein in the absence of any of the above criteria for active disease are not sufficient for protocol therapy.

• Serum creatinine <1.5 mg/dl.

• Bilirubin must be <2 mg/dl, unless secondary to tumor, obtained within 2 weeks prior to randomization.

• Age >18 years.

• Not pregnant (confirmed by serum pregnancy test in females of reproductive potential) or breast feeding, because it is unknown what effect these drugs will have on children.

• ECOG performance status 0-2.

• AST or ATL >2x upper limit of normal unless related to CLL.

• Subject has provided written informed consent.

Exclusion criteria:

• Subjects with autoimmune anemia or thrombocytopenia are not eligible.

• No prior cytotoxic chemotherapy. Patients with a history of steroid treatment for CLL, autoimmune hemolytic anemia, or autoimmune thrombocytopenia are not eligible.

• Subjects with active infections requiring oral or intravenous antibiotics until resolution of the infection and completion of therapeutic antibiotics.

• Women of childbearing potential and sexually active males who refuse to use an accepted and effective method of contraception.

• Subjects with a second malignancy other than basal cell carcinoma of the skin or in situ carcinoma of the cervix are not eligible unless the tumor was treated with curative intent at least two years previously.

• History of HIV

• CNS disease

• History of psychiatric disorder that would make it difficult to enroll and follow the patient on trial.

• New York Heart Classification III or IV heart disease.

• Hepatitis BsAg or Hepatitis C positive.

Study Design

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Chronic Lymphocytic Leukemia
• Leukemia
• Leukemia, Lymphocytic, Chronic, B-Cell
• Leukemia, Lymphoid

Intervention

Drug:
• Fludarabine
Fludarabine is usually administered by IV infusion over 30 minutes or longer.
• Cyclophosphamide
The dosage is a solution of 20 mg/mI. IV infusion over 1 hour.
• Rituximab
First Infusion: The rituximab solution for infusion should be administered intravenously at an initial rate of 50 mg/hr. Subsequent rituximab infusions can be administered at an initial rate of 100 mg/hr, and increased by 100 mg/hr increments at 30-minute intervals, to a maximum of 400 mg/hr as tolerated.

Locations

Country	Name	City	State
United States	Hillman Cancer Center	Pittsburgh	Pennsylvania

Sponsors (3)

Lead Sponsor	Collaborator
University of Pittsburgh	Biogen, Genentech, Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Tolerability of Rituximab, Cyclophosphamide and Fludarabine in Patients With Previously Untreated CLL/SLL	The number of patients who experience any grade 3-5 toxicity.	Duration of treatment on study	Yes
Primary	Efficacy of Rituximab, Cyclophosphamide and Fludarabine in Patients With Previously Untreated CLL/SLL	The number of patients who experience a complete clinical response.	Three months after the sixth cycle (9 months)	No
Secondary	Overall Survival Rate	The percentage of participants who are still alive.	Five years after starting rituximab, cyclophosphamide and fludarabine	No
Secondary	Duration of Response	The length of time for which the complete response is maintained.	From complete response to the time of progressive disease, death or last clinical examination	No